Levetiracetam-d3(Synonyms: 左乙拉西坦 d3)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Levetiracetam-d3 (Synonyms: 左乙拉西坦 d3)

Levetiracetam-d3 是 Levetiracetam 的氘代物。Levetiracetam是一种抗癫痫药,结合突触小泡蛋白 SV2A。 Levetiracetam增强Temozolomide 对胶质母细胞瘤干细胞增殖和凋亡的影响。Levetiracetam调节 HDAC 水平,最终使 MGMT 沉默从而提高 Temozolomide的有效性。化学增敏剂。

Levetiracetam-d3(Synonyms: 左乙拉西坦 d3)

Levetiracetam-d3 Chemical Structure

CAS No. : 1217851-16-5

规格 是否有货
1 mg Check price and availability
10 mg Check price and availability

* Please select Quantity before adding items.

生物活性

Levetiracetam-d3 is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent[1][2].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

173.23

Formula

C8H11D3N2O2

CAS 号

1217851-16-5

中文名称

左乙拉西坦 d3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Bianca Maria Scicchitano, et al. Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Cancer Cell Int. 2018 Sep 10;18:136.

    [3]. Delia M Talos, et al. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model. Pediatr Res. 2013 Jan;73(1):24-30.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务